Silo Pharma, Inc. (SILO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Silo Pharma, Inc. (SILO) Healthcare & Pipeline Overview

Silo Pharma Inc., a developmental-stage biopharmaceutical company, focuses on innovative treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases. Utilizing traditional and psychedelic therapies, Silo Pharma collaborates with leading universities to develop novel drug delivery systems, positioning itself in the competitive biotechnology landscape.

What Is the Investment Thesis for SILO?

Silo Pharma Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on underserved conditions, including psychiatric disorders and CNS diseases, positions it to capitalize on the growing demand for innovative treatments in these areas. The development of both traditional and psychedelic therapies provides diversification and potential for breakthrough treatments. Key value drivers include the successful advancement of its lead programs, SPC-15 and SP-26, through clinical trials and regulatory approval. The collaborations with Columbia University and the University of Maryland, Baltimore, enhance research capabilities and credibility. However, the company's developmental stage and limited financial resources pose significant risks. With a market cap of $3.09M and negative profit and gross margins of -7041.1% and -806.4% respectively, Silo Pharma's financial viability depends on securing additional funding and achieving clinical success. The company's beta of 0.61 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

SILO Key Highlights

Silo Pharma is a developmental stage biopharmaceutical company focusing on underserved conditions, including psychiatric disorders and CNS diseases.

• The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
• Silo Pharma is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.
• The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.
• Silo Pharma reported a negative profit margin of -7041.1% and a negative gross margin of -806.4%.

Who Are SILO's Competitors?

SILO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SILO's Key Strengths?

Innovative drug delivery systems.

• Strategic collaborations with universities.
• Focus on underserved medical needs.
• Pipeline of both traditional and psychedelic therapies.

What Are SILO's Weaknesses?

Developmental stage company with limited revenue.

• Small team and limited resources.
• High dependence on external funding.
• Significant regulatory and clinical trial risks.

What Could Drive SILO Stock Higher?

Clinical trial initiation for SPC-15 in PTSD patients.

• Preclinical data release for SPC-14 in Alzheimer's disease.
• Expansion of collaborations with Columbia University and the University of Maryland, Baltimore.
• Securing additional funding through grants and venture capital.
• Regulatory submissions for SP-26 in fibromyalgia.

What Are the Key Risks for SILO?

Financial-distress signal — its Altman Z-Score of -4.95 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-88.4%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures and regulatory rejections.
• Competition from larger pharmaceutical companies.
• Intellectual property challenges and patent expirations.
• Dependence on external funding and limited financial resources.
• Economic downturn and reduced investor interest in biotechnology.

What Are the Growth Opportunities for SILO?

• Successful clinical trials and regulatory approval could establish SPC-15 as a leading intranasal treatment, offering a non-invasive and convenient alternative to existing therapies. The company's collaboration with Columbia University provides a strong foundation for clinical development and commercialization. The timeline for potential market entry is estimated at 3-5 years, contingent on clinical trial outcomes and regulatory review.
• Development of SP-26 for Fibromyalgia and Chronic Pain: SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief, addresses a significant unmet need in the pain management market. The global market for pain management is expected to reach $83 billion by 2027. A successful SP-26 product could provide sustained pain relief and reduce the reliance on opioid-based medications. The company's partnership with the University of Maryland, Baltimore, supports the development and testing of this innovative drug delivery system. Market entry is projected within 4-6 years, pending clinical trial results and regulatory approvals.
• Expansion of Preclinical Programs for Alzheimer's and MS: Silo Pharma's preclinical programs, SPC-14 for Alzheimer's disease and SPU-16 for multiple sclerosis (MS), represent long-term growth opportunities in large and underserved markets. The Alzheimer's disease market is projected to reach $12 billion by 2028, while the MS market is expected to reach $28 billion by 2027. Successful development of these programs could lead to breakthrough treatments for these debilitating conditions. The timeline for potential market entry is estimated at 5-7 years, requiring significant investment in research and development.
• Strategic Partnerships and Collaborations: Silo Pharma can leverage strategic partnerships and collaborations to expand its pipeline and access new markets. Collaborating with other pharmaceutical companies, research institutions, or technology providers could accelerate the development and commercialization of its therapeutic candidates. These partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. The timeline for establishing new partnerships is ongoing, with potential agreements expected within the next 1-3 years.
• Expansion into Psychedelic-Assisted Therapies: Silo Pharma's focus on psychedelic treatments aligns with the growing interest in the therapeutic potential of psychedelics for mental health disorders. The market for psychedelic-assisted therapies is projected to reach $10 billion by 2027. By developing innovative formulations and delivery systems for psychedelic compounds, Silo Pharma can capitalize on this emerging market. The timeline for potential market entry is estimated at 3-5 years, contingent on regulatory changes and clinical trial outcomes.

What Are SILO's Competitive Advantages?

• Intellectual property protection through patents and proprietary formulations.
• Strategic collaborations with leading universities and research institutions.
• Focus on underserved conditions with limited treatment options.
• Innovative drug delivery systems enhancing efficacy and patient compliance.

What Does SILO Do?

Silo Pharma Inc., founded in 2010 and based in Sarasota, Florida, operates as a developmental stage biopharmaceutical company. Originally named Uppercut Brands, Inc., the company rebranded in September 2020 to reflect its strategic shift towards pharmaceutical development. Silo Pharma is dedicated to creating innovative therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. The company's approach involves developing both traditional therapies and psychedelic treatments, focusing on novel formulations and drug delivery systems to enhance efficacy and patient outcomes. Silo Pharma's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders, offering a potentially more convenient and effective delivery method. SP-26, another key program, is a time-release ketamine-loaded implant designed for fibromyalgia and chronic pain relief, aiming to provide sustained pain management. In addition to these programs, the company has two preclinical programs: SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). These programs highlight Silo Pharma's commitment to addressing a wide range of neurological and psychiatric disorders. Silo Pharma's research and development efforts are significantly enhanced through collaborations with Columbia University and the University of Maryland, Baltimore. These partnerships provide access to cutting-edge research, expertise, and resources, accelerating the development and validation of its therapeutic candidates. With a small team of 3 employees, Silo Pharma leverages these collaborations to maximize its research capabilities and advance its pipeline.

What Products and Services Does SILO Offer?

• Develop therapeutics for stress-induced psychiatric disorders.
• Create treatments for chronic pain conditions.
• Research therapies for central nervous system (CNS) diseases.
• Focus on traditional therapies and psychedelic treatments.
• Develop novel drug formulations and delivery systems.
• Collaborate with universities for research and development.
• Target underserved conditions with unmet medical needs.

How Does SILO Make Money?

• Develop and patent novel therapeutic compounds.
• Outsource manufacturing and clinical trials.
• License or partner with larger pharmaceutical companies for commercialization.
• Secure funding through grants, venture capital, and public offerings.

What Industry Does SILO Operate In?

Silo Pharma operates in the biotechnology industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for treatments for psychiatric disorders, chronic pain, and CNS diseases is substantial and growing, driven by increasing prevalence and unmet medical needs. Companies like BDRX, CANF, CMND, CNSP, and GRI represent the competitive landscape, each pursuing different therapeutic approaches and target markets. Silo Pharma's focus on both traditional and psychedelic therapies, combined with its collaborations with leading universities, differentiates it from some competitors. The industry is also subject to evolving regulatory frameworks and intellectual property challenges, requiring companies to navigate complex legal and ethical considerations.

Who Are SILO's Key Customers?

• Pharmaceutical companies seeking to license or acquire novel therapeutics.
• Patients suffering from psychiatric disorders, chronic pain, and CNS diseases.
• Healthcare providers prescribing treatments for these conditions.
• Research institutions and universities collaborating on drug development.

Wall Street analysts project Silo Pharma, Inc. revenue of about $72K for fiscal 2026, with EPS near $-10.80.

Quarterly Financial Performance: Silo Pharma, Inc.

Revenue for Silo Pharma, Inc. came in at $18K during Q1 2026. The company recorded a net loss of $1.6M, with diluted EPS of $-1.80. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

SILO Valuation & Market Position

With a $3.09M market cap, Silo Pharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SILO's quantitative score of 18/100 is below the peer average of 50/100.

Return on equity for Silo Pharma, Inc. stands at -88.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.0%, showing how much profit it generates from its asset base. A current ratio of 9.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -171.2%, the inverse of the P/E and a quick read on earnings relative to price.

Silo Pharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.95 places it in the distress zone, a signal of elevated financial risk.

Silo Pharma, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 275.6% below estimates on average.

Company Profile

Silo Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Eric Weisblum. SILO has traded publicly since 2021.

SILO Financials

SILO Latest News

SILO Analyst Consensus

SILO MoonshotScore

What Investors Ask About Silo Pharma, Inc. (SILO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources